Abstract
We present the case of a 53-year-old woman who developed systemic lupus erythematosus (SLE) after being treated with interferon-alpha (IFN-α) for cryoglobulinemic vasculitis associated with hepatitis C virus (HCV) infection. Her cryoglobulinemic vasculitis resolved rapidly with IFN-α treatment. However, after 10 months of IFN-α therapy, she developed a photosensitive malar rash, oral ulcers, arthralgias, lymphopenia, and anti-SSA autoantibodies. She was diagnosed with SLE induced by IFN-α therapy. IFN-α was discontinued, she was treated with a short course of prednisone and hydroxychloroquine, and she improved rapidly. This is the first report of IFN-α-induced SLE complicating treatment of cryoglobulinemic vasculitis associated with HCV infection. The development of SLE during therapy with IFN-α could be due to direct immunomodulation by IFN-α, and review of experimental data and prior case reports suggests a pathogenic role for IFN-α in SLE.
Similar content being viewed by others
References
Ioannou Y, Isenberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431–1442
Krause I, Valesini G, Scrivo R, Shoenfeld Y (2003) Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115:390–397
Ronnblom LE, Alm GV, Oberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207–210
Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536–1537
Mehta ND, Hooberman AL, Vokes EE, Neeley S, Cotler S (1992) 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy. Am J Hematol 41:141
Tolymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C (1992) Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 120:429–432
Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65:70–74
Hory B, Blanc D, Saint-Hiller Y (1992) Systemic lupus erythematosus-like syndrome induced by alpha-interferon therapy. Eur J Med 1:379
Flores A, Olive A, Feliu E, Tena X (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33:787
Yoshida A, Takeda A, Koyama K, Morozumi K, Oikawa T (1994) Systemic lupus erythematosus with nephropathy after interferon-α 2A therapy. Clin Rheumatol 13:382
Morris LF, Lemak NA, Arnett FC, Jordon RE, Duvic M (1996) Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 89:810–814
Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K (2000) Systemic lupus erythematosus after α-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 95:310
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237–2242
Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T (1987) Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 70:562–569
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540–1543
Author information
Authors and Affiliations
Corresponding author
Additional information
No financial support or conflict of interest to declare
Rights and permissions
About this article
Cite this article
Niewold, T.B., Swedler, W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24, 178–181 (2005). https://doi.org/10.1007/s10067-004-1024-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-1024-2